Charts of the Day: Incyte, WD-40, Gain Capital Holdings

Incyte's experimental melanoma treatment fails to meet its phase 3 primary endpoint; WD-40 beat on earnings, missed on revenue and sales growth; Gain Capital Holdings to continue rollout of its cryptocurrency offerings

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes